z-logo
open-access-imgOpen Access
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis
Author(s) -
Zhao Helong,
Ahirwar Dinesh K.,
Oghumu Steve,
Wilkie Tasha,
Powell Catherine A.,
Nasser Mohd W.,
Satoskar Abhay R.,
Li Dean Y.,
Ganju Ramesh K.
Publication year - 2016
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2015.10.007
Subject(s) - angiogenesis , metastasis , cancer research , breast cancer , biology , cancer , tumor microenvironment , cancer cell , vascular endothelial growth factor , immunology , vegf receptors , genetics , tumor cells
Targeting tumor angiogenesis is a promising alternative strategy for improvement of breast cancer therapy. Robo4 (roundabout homolog 4) signaling has been shown to protect endothelial integrity during sepsis shock and arthritis, and inhibit Vascular Endothelial Growth Factor (VEGF) signaling during pathological angiogenesis of retinopathy, which indicates that Robo4 might be a potential target for angiogenesis in breast cancer. In this study, we used immune competent Robo4 knockout mouse model to show that endothelial Robo4 is important for suppressing breast cancer growth and metastasis. And this effect does not involve the function of Robo4 on hematopoietic stem cells. Robo4 inhibits breast cancer growth and metastasis by regulating tumor angiogenesis, endothelial leakage and tight junction protein zonula occludens protein‐1 (ZO‐1) downregulation. Treatment with SecinH3, a small molecule drug which deactivates ARF6 downstream of Robo4, can enhance Robo4 signaling and thus inhibit breast cancer growth and metastasis. SecinH3 mediated its effect by reducing tumor angiogenesis rather than directly affecting cancer cell proliferation. In conclusion, endothelial Robo4 signaling is important for suppressing breast cancer growth and metastasis, and it can be targeted (enhanced) by administrating a small molecular drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here